Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — Q1 2023 Earnings Presentation
27 slides from Burjeel's earnings presentation, May 2023
Slide 1: Burjeel Holdings Q1-FY2023 Earnings Presentation
Burjeel Holdings Q1-FY2023 Earnings Presentation May 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC based on publicly available information and non-public information to assist you in making a preliminary analysis of the content referenced herein solely for informational purposes. It should not be construed as an offer to sell
Slide 3: Agenda and Presenters
Agenda and Presenters John Sunil 01 Business Overview Chief Executive Officer 02 Performance Highlights 03 Strategy Overview Muhammed Shihabuddin Chief Financial Officer 04 Group Financial Review 05 Segmental Review Chetan Sehgal 06 Outlook Director - Strategy and Investments Head of Investor Relati
Slide 4: Business Overview
Business Overview A full Healthcare Services ecosystem with a comprehensive offering across the entire patient journey, delivered through a portfolio of targeted brands 16 16 8 15 7 Hospitals Polyclinics Specialty Pharmacies Other Centres 24 Medical Centers Portfolio of brands, each targeted at dist
Slide 5: Key Q1 2023 Highlights
Key Q1 2023 Highlights Strong top and Network expansion Patient footfall Enhanced Range bottom-line growth progressing increasing of Offerings Revenue of AED 1,085 million, up On track to add 100+ new Overall patient footfall increased Launched The Paley Middle East 12% over Q1FY22 inpatient beds an
Slide 6: Focused Strategy, Clear Delivery
Focused Strategy, Clear Delivery Ramp Up Of Increasing Operational Geographic Growth Assets Patient Yield Excellence Expansion Young asset fleet, with growth Elevate the delivery of Centralization and Deliver on our KSA entry to be driven by utilisation high-value complex care, digitization to ensur
Slide 7: Group Financial Review
Group Financial Review 7
Slide 8: Revenue, EBITDA & Net Profit
Revenue, EBITDA & Net Profit REVENUE (AEDm)1 EBITDA (AEDm)1 NET PROFIT (AEDm)1 11.6% 13.4% 972 21085 21.9% 22.3% 7 18 242 16 107 213 43.4% 86 4 13 30 11.2% 1 21 8.7% 863 958 216 177 121 85 -9 Q1 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q1 FY2022 Q1 FY2023 EBITDA Margin Hospitals Medical Centers Pharmacies Other
Slide 9: P&L Overview
P&L Overview Group Q1-FY22 Q1-FY23 Change Inventories Consumed 226 252 11.6% ▪ Inventory consumption as a percentage of revenue was % of Revenue 23.2% 23.2% maintained at the same level as prior year. Doctors’ and other employees 1 413 469 13.7% ▪ Manpower costs increased slightly as a percentage of
Slide 10: Group Net Working Capital Analysis
Group Net Working Capital Analysis TRADE RECEIVABLES (AEDm)1 INVENTORY (AEDm)1 TRADE ACCOUNT PAYABLE (AEDm)1 96 96 96 84 266 229 235 1,155 1,052 240 641 666 FY2022 Q1 FY2023 FY2022 Q1 FY2023 FY2022 Q1 FY2023 Days Sales Outstanding2 Days Inventory Outstanding3 Days Payables Outstanding4 ▪ Receivable
Slide 11: Group capital structure
Group capital structure FY2021 FY2022 Q1 FY23 Bank Balances and Cash 134 150 172 Interest bearing loans and borrowings& Bank Overdraft decreased by AED 2,038 million between Dec’21 to Dec’22, mainly as a result of the one-time settlement of Interest bearing loans and borrowings 3,208 1,261 1,232 loa
Slide 12: Segmental Review: Hospitals
Segmental Review Hospitals 12
Slide 13: Hospitals Segment | Financial Performance Update
Hospitals Segment | Financial Performance Update REVENUES (AEDm)1 EBITDA (AEDm) 12.3% Hospitals Segment Q1-FY22 Q1-FY23 Change Inventories Consumed 230 264 15.1% 897 1,007 % of Revenue 25.6% 26.3% 16 Doctors’ and other employees 1 362 396 9.4% 8 % of Revenue 40.3% 39.3% 375 293 Provision for ECL 25
Slide 14: Hospitals Segment | Operational Performance Update
Hospitals Segment | Operational Performance Update OUTPATIENT FOOTFALL (in 000s) INPATIENT FOOTFALL (in 000s) 64.8% 63.5% 50.2% 26.9% 60.2% 17.1% 35 27 1,069 913 Q1 FY2022 Q1 FY2023 Q1 FY2022 Q1 FY2023 % OP Utilisation % Bed Occupancy ▪ The ramp up in utilisation of assets, in particular, at BMC, dr
Slide 15: Burjeel Medical City Performance
Burjeel Medical City Performance TOTAL PATIENTS (IN 000s) REVENUE (AEDm)1 EBITDA (AEDm)1 32.6% 247.6% 34.9% 38.2% 5.5% 14.4% 29.1% 40.6% 99 232 175 34 55 10 Q1 FY2022 Q1 FY2023 Q1 FY2022 Q1 FY2023 Q1 FY2022 Q1 FY2023 % OP capacity utilisation % EBITDA Margin % IP bed occupancy ▪ Burjeel Medical City
Slide 16: Segmental Review: Medical Centers
Segmental Review Medical Centers 16
Slide 17: Medical Centers Segment | Financial Performance Update
Medical Centers Segment | Financial Performance Update REVENUE (AEDm)1 EBITDA (AEDm) Medical Centers Segment Q1-FY22 Q1-FY23 Change 74.0% 19.0% 75.1% Inventories Consumed 20 25 22.6% % of Revenue 22.1% 22.8% 108 Doctors’ and other employees 1 38 41 10.2% 91 1 % of Revenue 41.3% 38.3% Provision for E
Slide 18: Network Evolution
Network Evolution 18
Slide 19: Middle East & Africa Key Regions; Saudi Arabia Core to Growth Strategy
Middle East & Africa Key Regions; Saudi Arabia Core to Growth Strategy Key region of focus – Middle East & Africa Target markets 1 KSA ⚫ First Leejam JV rehabilitation and wellness clinics expected to open in Q4 2023 ⚫ O&M opportunities being explored 2 Egypt Saudi Arabia (and other UAE neighbouring
Slide 20: Expanding Our Healthcare Infrastructure
Expanding Our Healthcare Infrastructure Launch of five new medical centers in FY2023 The planned launch of five medical centers by Q3 FY2023 will allow the group to tap into new markets and attract more patients, resulting in increased revenue streams and improved profitability. We will also benefit
Slide 21: Outlook
Outlook 21
Slide 22: FY 2023 Outlook
FY 2023 Outlook REVENUE GROWTH EBITDA MARGIN MAINTENANCE CAPEX NET LEVERAGE o Group revenue is o EBITDA margin expected o Maintenance CAPEX o Net Debt/EBITDA1 of expected to grow to improve to at least 2021 expected to be less than 2.5x to be organically in the high- levels approximately 2.5% of mai
Slide 23: Q&A
Q&A 23
Slide 24: Appendix
Appendix 24
Slide 25: Financial summary Q1-FY2023 & Q1-FY2022
Financial summary Q1-FY2023 & Q1-FY2022 Group Financial Summary Segmental Financial Summary AED Million Q1 FY22 Q1 FY23 YoY % AED Millions Q1-FY22 Q1-FY23 QoQ % Revenue 972 1,085 11.6% Revenue 972 1,085 11.6% 1 Opex -759 -843 11.1% Hospitals 863 958 10.9% 2 EBITDA 213 242 13.4% Medical Centers 86 10
Slide 26: A Young Asset Fleet with Growth to be Driven by Utilisation Ramp-Up
A Young Asset Fleet with Growth to be Driven by Utilisation Ramp-Up Asset maturity split for hospitals1 Inpatient bed occupancy2 16 hospitals 60% 50% 19% 25% Matured Growth - medium Q1 FY2022 Q1 FY2023 Growth - high Group Outpatient utilisation3 56% 74% 73% We have significant headroom remaining, wh
Slide 27: Burjeel Holdings
Burjeel Holdings Q1-FY2023 Earnings Presentation May 2023